Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation – summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019

Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation – summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019

Abstract Concerning development of medicinal products, children belong to a so-called “special population” for which additional legislation applies: Regulation (EC) No 1901/2006 on medicinal products for paediatric use sets up a system of requirements, rewards and incentives to ensure that medicinal...

Full description

Bibliographic Details
Main Authors: V. Mahler, D. Mentzer, A. Bonertz, A. Muraro, P. Eigenmann, J. Bousquet, S. Halken, O. Pfaar, M. Jutel, U. Wahn, S. Vieths, S. Kaul
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Clinical and Translational Allergy
Subjects:
Allergen Immunotherapy (AIT)
Children
Paediatric Investigation Plan (PIP)
Therapy Allergen Ordinance (TAO)
Paediatric Committee (PDCO)
European Medicines Agency (EMA)
Online Access:http://link.springer.com/article/10.1186/s13601-020-00327-w

Internet

http://link.springer.com/article/10.1186/s13601-020-00327-w

Similar Items